Search Videos by Topic or Participant
Browse by Series:

Reimbursement for Oncology Treatment

Panelists: Andrew L. Pecora, MD, FACP, CPE, JTCC
Published: Tuesday, May 19, 2015
For High-Definition, Click
The now-repealed Sustainable Growth Rate (SGR) formula was created via the Balanced Budget Act of 1997 to prevent Medicare physician payments from ballooning beyond the government’s ability to pay, explains Pecora. Unfortunately, the SGR caused huge payment uncertainty for physicians.

It was repealed in March via the passage of the Medicare Access and CHIP Reauthorization Act of 2015, which established performance incentives to encourage physicians to improve health outcomes and participate in cost-saving models of care.

Historically, there used to be a substantial margin on oncology medication prices that enabled oncologists to hire staff and enjoy an acceptable standard of living, comments Pecora. The pendulum has swung the other way, and margins on care delivery have shrunk dramatically, placing “incredible stress” on the healthcare system, he says.

The rise of immunotherapy agents, he adds, has compounded the problem. They work, but are incredibly expensive. Therefore, their increasing use for an array of cancer types and for combination therapy may lead to a higher cost burden, he explains.
Slider Left
Slider Right
For High-Definition, Click
The now-repealed Sustainable Growth Rate (SGR) formula was created via the Balanced Budget Act of 1997 to prevent Medicare physician payments from ballooning beyond the government’s ability to pay, explains Pecora. Unfortunately, the SGR caused huge payment uncertainty for physicians.

It was repealed in March via the passage of the Medicare Access and CHIP Reauthorization Act of 2015, which established performance incentives to encourage physicians to improve health outcomes and participate in cost-saving models of care.

Historically, there used to be a substantial margin on oncology medication prices that enabled oncologists to hire staff and enjoy an acceptable standard of living, comments Pecora. The pendulum has swung the other way, and margins on care delivery have shrunk dramatically, placing “incredible stress” on the healthcare system, he says.

The rise of immunotherapy agents, he adds, has compounded the problem. They work, but are incredibly expensive. Therefore, their increasing use for an array of cancer types and for combination therapy may lead to a higher cost burden, he explains.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x